Evidence map›Paper›PMID 38779853›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2024

Cancer Incidence After Diagnosis of Abdominal Aortic Aneurysm-Brief Report.

Lingfeng Luo, Allen M Haas, Caitlin F Bell, Richard A Baylis, Shaunak S Adkar, Changhao Fu, Ivan Angelov, Sharon H Giordano, Derek Klarin, Nicholas J Leeper and 1 more

Abstract read
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Cardiovascular Disease and Cancer: A Dangerous Liaison.Arteriosclerosis, thrombosis, and vascular biology · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Lingfeng LuoDivision of Vascular Surgery, Department of Surgery (L.L., C.F.B., R.A.B., S.S.A., C.F., D.K., N.J.L.), Stanford University School of Medicine, Palo Alto, CA.ORCID 0000-0002-0601-0053
Allen M HaasDepartment of Health Services Research (A.M.H., S.H.G.), University of Texas MD Anderson Cancer Center, Houston.ORCID 0000-0001-6214-4446
Caitlin F BellDivision of Vascular Surgery, Department of Surgery (L.L., C.F.B., R.A.B., S.S.A., C.F., D.K., N.J.L.), Stanford University School of Medicine, Palo Alto, CA.
Richard A BaylisDivision of Vascular Surgery, Department of Surgery (L.L., C.F.B., R.A.B., S.S.A., C.F., D.K., N.J.L.), Stanford University School of Medicine, Palo Alto, CA.ORCID 0000-0001-7040-7920
Shaunak S AdkarDivision of Vascular Surgery, Department of Surgery (L.L., C.F.B., R.A.B., S.S.A., C.F., D.K., N.J.L.), Stanford University School of Medicine, Palo Alto, CA.
Changhao FuDivision of Vascular Surgery, Department of Surgery (L.L., C.F.B., R.A.B., S.S.A., C.F., D.K., N.J.L.), Stanford University School of Medicine, Palo Alto, CA.ORCID 0000-0001-7568-3369
Ivan AngelovSchool of Medicine, Baylor College of Medicine, Houston, TX (I.A.).ORCID 0000-0003-1597-1873
Sharon H GiordanoDepartment of Health Services Research (A.M.H., S.H.G.), University of Texas MD Anderson Cancer Center, Houston.ORCID 0000-0002-8700-2767
Derek KlarinDivision of Vascular Surgery, Department of Surgery (L.L., C.F.B., R.A.B., S.S.A., C.F., D.K., N.J.L.), Stanford University School of Medicine, Palo Alto, CA.ORCID 0000-0002-4636-5780
Nicholas J Leeper *Division of Vascular Surgery, Department of Surgery (L.L., C.F.B., R.A.B., S.S.A., C.F., D.K., N.J.L.), Stanford University School of Medicine, Palo Alto, CA.ORCID 0000-0002-0905-2806
Kevin T Nead *Department of Radiation Oncology (K.T.N.), University of Texas MD Anderson Cancer Center, Houston.ORCID 0000-0001-9680-8298

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Medical Scientist Training Program Training GrantT32GM145449 · NIGMS · DUKE UNIVERSITY · PI Christopher D Kontos · 2022 to 2026
$6.6M
Clonal expansion, resistance to efferocytosis and innate immunity in atherosclerosisR35HL144475 · NHLBI · STANFORD UNIVERSITY · PI LEEPER, NICHOLAS JAMES · 2019 to 2024
$5.1M
Impact of clonal hematopoiesis mutations on toxicity and outcomes following oncologic therapyK08CA263313 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI NEAD, KEVIN THOMAS · 2021 to 2025
$1.2M
Clonal hematopoiesis and risk of peripheral artery diseaseIK2BX005759 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI KLARIN, DEREK · 2022 to 2023
–
American Heart Association-American Stroke Association 23SCEFIA1153369BLRD VA IK2 BX005759NCI NIH HHS K08 CA263313NCI NIH HHS L30 CA253796NCI NIH HHS P30 CA016672NHLBI NIH HHS R35 HL144475NIGMS NIH HHS T32 GM145449
6 · The paper itself

Abstract

backgroundEpidemiological and mechanistic data support a potential causal link between cardiovascular disease (CVD) and cancer. Abdominal aortic aneurysms (AAAs) represent a common form of CVD with at least partially distinct genetic and biologic pathogenesis from other forms of CVD. The risk of cancer and how this risk differs compared with other forms of CVD, is unknown among AAA patients. We conducted a retrospective cohort study using the IBM MarketScan Research Database to test whether individuals with AAA have a higher cancer risk independent of traditional shared risk factors.

methodsAll individuals ≥18 years of age with ≥36 months of continuous coverage between 2008 and 2020 were enrolled. Those with potential Mendelian etiologies of AAA, aortic aneurysm with nonspecific anatomic location, or a cancer diagnosis before the start of follow-up were excluded. A subgroup analysis was performed of individuals having the Health Risk Assessment records including tobacco use and body mass index. The following groups of individuals were compared: (1) with AAA, (2) with non-AAA CVD, and (3) without any CVD.

resultsThe propensity score-matched cohort included 58 993 individuals with AAA, 117 986 with non-AAA CVD, and 58 993 without CVD. The 5-year cumulative incidence of cancer was 13.1% (12.8%-13.5%) in participants with AAA, 10.1% (9.9%-10.3%) in participants with non-AAA CVD, and 9.6% (9.3%-9.9%) in participants without CVD. Multivariable-adjusted Cox proportional hazards regression models found that patients with AAA exhibited a higher cancer risk than either those with non-AAA CVD (hazard ratio, 1.28 [95% CI, 1.23-1.32];

conclusionsPatients with AAA may have a unique risk of cancer requiring further mechanistic study and investigation of the role of enhanced cancer screening.

Indexed as

Aortic Aneurysm, AbdominalNeoplasmsAdultAgedAged, 80 and overDatabases, FactualFemaleHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsUnited Statesaortic aneurysmbiological productsrisk assessmentsmokingtobacco use

Identifiers

PMID38779853
PMCPMC11209781

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.